Sarepta Therapeutics, Inc. (SRPT) earnings
SRPT earnings moved a median of -1.37% by the close. Quarterly and annual SRPT reports and results, each read against the price at its own news timestamp. Back to the SRPT overview →
26 measured SRPT earnings events.
Where these SRPT earnings landedvs 26 measured SRPT earnings reactions
| Middle 50% of SRPT earnings reactions | -5.84% to +0.74% |
|---|---|
| Median reaction (to close) | -1.37% |
| Measured reactions | 26 |
Point-in-time · zero look-ahead
Half of the 26 SRPT earnings events with a measured close landed between -5.84% and +0.74%; 35% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Sarepta Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.44% | +0.72% | |
| Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments | Press release | +1.44% | +0.72% | |
| Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results | Press release | -0.12% | -2.35% | |
| Form 10-Q Sarepta Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.61% | -5.84% | |
| Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments | Press release | +0.61% | -5.84% | |
| Sarepta Therapeutics to Announce First Quarter 2026 Financial Results | Press release | -1.28% | -1.99% | |
| Form 10-K Sarepta Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +2.39% | +0.74% | |
| Form 10-Q Sarepta Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.17% | -0.79% | |
| Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE | Press release | +4.63% | +6.30% | |
| Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results | Press release | +1.90% | +3.15% | |
| Form 10-Q Sarepta Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +2.25% | -1.59% | |
| Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments | Press release | +2.25% | -1.59% | |
| Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results | Press release | -0.40% | -0.06% | |
| Form 10-Q Sarepta Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.57% | -8.20% | |
| Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments | Press release | -0.57% | -8.20% | |
| Sarepta Therapeutics to Announce First Quarter 2025 Financial Results | Press release | +0.77% | +6.56% | |
| Form 10-K Sarepta Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.12% | -5.18% | |
| Form 10-Q Sarepta Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -3.06% | -9.05% | |
| Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments | Press release | -3.06% | -9.05% | |
| Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results | Press release | -0.24% | -0.47% | |
| Form 10-Q Sarepta Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.30% | +1.41% | |
| Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments | Press release | +0.30% | +1.41% | |
| Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results | Press release | +0.99% | -1.14% | |
| Form 10-Q Sarepta Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -6.69% | |
| Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments | Press release | +0.00% | -6.69% | |
| Sarepta Therapeutics to Announce First Quarter 2024 Financial Results | Press release | +0.12% | +5.60% |
Keep exploring
More SRPT: analyst actions → · SEC filings → · SRPT overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| NuVasive, Inc. (NUVA) | 1,226 | +0.03% | 51% |
| DENTSPLY SIRONA Inc. (XRAY) | 1,226 | +0.05% | 52% |
| Orthofix Medical Inc. (OFIX) | 1,217 | +0.06% | 51% |
| IMMUNOMEDICS (IMMU) | 1,213 | -0.08% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.